Chronic kidney disease (CKD) is a public health challenge, as it has a prevalence of 11% and is the 14th-leading cause of death worldwide (12.2 deaths per 100,000 people). Since 1990, deaths from CKD have increased at a higher rate than for any other cause except for deaths from complications of HIV infection.1 Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are the standard of care to delay the progression of earlier stages of CKD to kidney failure in patients with proteinuria irrespective of the primary cause of kidney disease; in addition, these agents are associated with reduction in cardiovascular risk.